Emerging Biomarkers in Alcoholic Liver Disease
Posted on: April 14, 2022
This is an archived edition of our email newsletter.
It’s Not Just Support. It’s Solutions.
Non-Invasive Biomarkers for Alcoholic Liver Disease Studies
Biomarkers of cell death and regeneration, inflammation, and immune response become useful tools as new potential Alcoholic Liver Disease (ALD) and Alcoholic Hepatitis (AH) treatment options are investigated. Serum biomarkers can provide valuable insights into:
- Disease severity and progression in ALD and AH research studies
- Mechanisms involved in ALD and AH pathogenesis
DiaPharma has the tools for ALD Research.
Measure hepatocyte apoptosis and/or necrosis with our Cytokeratin 18/Keratin 18 (CK18/K18) biomarkers:
- M30 Apoptosense® ccK18 ELISA
- Measures apoptosis
- M65® ELISA and M65® EpiDeath® K18 ELISA
- Measures total cell death
Additional Biomarkers of Interest:
- Osteopontin (OPN)
- Soluble CD163 (sCD163)
- Complement Factors 3a/5a/C5b-9
Visit diapharma.com for our comprehensive portfolio including biomarkers for Nonalcoholic Fatty Liver Disease (NAFLD) / Nonalcoholic Steatohepatitis (NASH) and Drug Induced Liver Injury (DILI).
All products are for research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, with support just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00894Rev01